Katrine Bosley is the chairman of Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA.
Bosley joined Arrakis’ board of directors in 2019. She was previously the CEO of Editas Medicine, a genome editing company and innovator of CRISPR technology. She led the company through its IPO and entry into clinical development.
The biotech executive was also the CEO of Avila Therapeutics beginning in 2009. Under her leadership, the company was a champion of the discovery and development of targeted covalent drugs. Bosley served as CEO until Avila was acquired by Celgene Corp. in 2012.
Earlier in her career, Bosley was the vice president of business development and strategic operations for Adnexus Therapeutics. The company developed a new class of protein therapeutics called Adnectins while Bosley was there. It was acquired by Bristol-Myers Squibb in 2007.
Bosley has also worked for Biogen in a business and market development role, for Highland Capital Partners in venture capital, and for Alkermes in regulatory affairs.
She was named “CEO of the Year” by Xconomy, listed among the “100 Most Creative People in Business” by Fast Company, one of “30 Global Game Changers” by Forbes, one of the “Top Ten Women in Biotech” by FierceBiotech, and “Entrepreneur of the Year” by the New England Venture Capital Association.
Bosley currently serves on the boards of Galapagos NV, Massachusetts Eye and Ear, and Genocea Biosciences. She has previously served on the boards of the Biotechnology Innovation Organization, Scholar Rock, and Coco Therapeutics Ltd. Additionally, in 2013, she joined The Wellcome Trust as part of the review committee member of the translation fund as well as becoming the entrepreneur-in-residence at the Broad Institute.
Bosley holds a bachelor of arts degree in biology from Cornell University.
What is Katrine Bosley's net worth?
The estimated net worth of Katrine Bosley is at least $1.58 million as of January 8th, 2019. Ms. Bosley owns 1,204,966 shares of Editas Medicine stock worth more than $1,578,505 as of December 22nd. This net worth estimate does not reflect any other investments that Ms. Bosley may own. Learn More about Katrine Bosley's net worth.
How do I contact Katrine Bosley?
Has Katrine Bosley been buying or selling shares of Editas Medicine?
Katrine Bosley has not been actively trading shares of Editas Medicine within the last three months. Most recently, Katrine Bosley sold 12,000 shares of the business's stock in a transaction on Tuesday, January 8th. The shares were sold at an average price of $25.27, for a transaction totalling $303,240.00. Following the completion of the sale, the chief executive officer now directly owns 1,204,966 shares of the company's stock, valued at $30,449,490.82. Learn More on Katrine Bosley's trading history.
Who are Editas Medicine's active insiders?
Are insiders buying or selling shares of Editas Medicine?
During the last year, Editas Medicine insiders bought shares 1 times. They purchased a total of 45,000 shares worth more than $253,800.00. During the last year, insiders at the sold shares 10 times. They sold a total of 133,590 shares worth more than $1,104,930.91. The most recent insider tranaction occured on December, 3rd when CEO Gilmore Neil O'neill sold 1,618 shares worth more than $3,365.44. Insiders at Editas Medicine own 1.9% of the company.
Learn More about insider trades at Editas Medicine. Information on this page was last updated on 12/3/2024.
